Referring Clinician
Please email all referrals to CentralReferrals@adhb.govt.nz (including Att: ACTC in email subject)
NOTE: referrals only accepted from oncologists/haematologists.
Email us for any other queries: infoACTC@adhb.govt.nz
| Tumour Stream | Trial Name | Study Description | Key Investigational Agent | Key Inclusion Criteria | Recruitment Status |
|---|---|---|---|---|---|
| All Cancers | BGB-A317-26808-101 (HPK2) | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Ad-vanced Solid Tumors | BGB-26808 (HPK1 Inhibitor) +/- Tislelizumab | Current recruitment for GC/GOJ expansion cohort 1L treatment Need to be able to swallow Adequate organ function No procedure significantly affecting GI function | Open |
| All Cancers | BGB-53038-101 Pan-KRAS | A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmaco-dynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification | BGB-53038 (Pan-KRAS Inhibitor) | Currently Phase 1a part A – limited to non-squamous NSCLC, CRC, PDAC, GC, GEJC or EAC Adequate organ function | Open |
| All Cancers | BG-68501-101 | A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants with Advanced Solid Tumors | BG-68501 BG-68501 + fulvestrant +/- BGB-43395 | Monotherapy – HR+/HER2- BC, PROC, SCLC, TNBC, endometrial, GC/GOJ, urothelial, prostate Combination cohort limited to HR+/HER2- BC At least 1L of prior systemic therapy for metastatic disease Prior endocrine therapy and CDK4/6 inhibitor in either adjuvant or metastatic setting Prior SERD permitted | Open – monotherapy cohort |
| Selected solid tumours | BG-C477-101 | A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients with Selected Advanced Solid Tumors | BG-C477 | Currently Phase 1a – limited to CRC, GC/GEJC, NSCLC, SCLC, PADC Need to have been treated with at least 2L SOC or no treatment available Non-CRC need serum CEA ≥ 5 ng/ml or CEA positivity on IHC Previous CEA targeting ADC or ADC containing TOP1 inhibitor not allowed Adequate organ function | Open |
| Lymphoma | BGB-16673-104 | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | SS1: BGB-16673 + Sonrotoclax (Bcl-2 inhibitor) SS2: BGB-16673 + Zanubrutinib (BTK inhibitor) SS3: BGB-16673 + Mosunetuzumab (CD20 x CD3 Bispecific Antibody) SS4: BGB-16673 + Glofitamab (CD20 x CD3 Bispecific Antibody) | Open | |
| Lymphoma | BGB-21447-101 | A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies | BGB-21447 (Bcl-2 inhibitor) | Open | |
| Lymphoma | BP41072 | AN OPEN-LABEL, PHASE I/II STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PRELIMINARY ANTI-TUMOR ACTIVITY OF ENGLUMAFUSP ALFA (RO7227166, A CD19 TARGETED 4-1BB LIGAND) IN COMBINATION WITH OBINUTUZUMAB AND IN COMBINATION WITH GLOFITAMAB FOLLOWING A PRE-TREATMENT DOSE OF OBINUTUZUMAB ADMINISTERED IN PARTICIPANTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA | Englumafusp alfa + Obinutuzumab + Glofitamab | Open | |
| Lymphoma | NP30179 | A multicenter, open-label, phase 1 study to evaluate the safety, efficacy, tolerability and pharmacokinetics of escalating doses of RO7082859 as a single agent and in combination with obinutuzumab administered after a fixed, single dose pre-treatment of obinutuzumab (Gazyva/Gazyvaro) in patients with relapsed/refractory B-cell non-hodgkin's lymphoma | Glofitamab + Obinutuzumab | Open | |
| Prostate | MK-365 | Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) | Cohort I currently open – t-NE mCRPC randomised to receive Carboplatin + etoposide +/- pembro | • Adenocarcinoma, neuroendocrine • Biopsiable disease from non-irradiated site (bone allowed for certain cohorts) • Prior anti PD1/PDL1, radiopharmaceuticals, superscan not permitted. | Open (Cohort I only) |
| Prostate | MK-2400-01A | A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02) | Open | ||
| Prostate | MK-5684-01A Substudy | A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) | Recruitment on temporary hold |